
    
      This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter
      study in adult subjects with ADHD.

      Eligible subjects will be randomly assigned in a 1:1 ratio to one of two treatment groups,
      1400 mg Metadoxine (MG01CI) and Placebo. The study will consist of three periods: a screening
      period of up to 2 weeks, a 6-week double-blind treatment period, and a 2-week safety
      follow-up period. The total duration of subject participation will be ~10 weeks.

      Overview of Study Visits

      Screening Period:

      Visit 1 - Screening/Baseline Visit (up to 14 days prior to dosing)

      Treatment Period:

      Visit 2 - Day 0 (Randomization Visit) Visit 3 - Day 7 ± 2 days Visit 4 - Day 14 ± 2 days
      Visit 5 - Day 28 ± 2 days Visit 6 - Day 42 ± 2 days

      Follow-up period:

      Visit 7 - Day 56 ± 3 days
    
  